In recent years, immune checkpoint inhibitors, such as programmed cell death protein-1 (PD-1) monoclonal antibodies, have shown promising results in the treatment of advanced HNSCC and have been recommended by international guidelines (8, 9). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.